Last reviewed · How we verify

NCT06644469

Whole Body Vibration in Middle Aged Men

Not yet recruiting NA Last updated 18 October 2024
What this trial tests

NA trial testing Dynatronics VF5 Model vibration platform in Bone Density in 34 participants. Not yet recruiting.

Timeline
15 October 2024
Primary endpoint
1 December 2024
15 December 2024

Quick facts

Lead sponsorJouf University
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment34
Start date15 October 2024
Primary completion1 December 2024
Estimated completion15 December 2024
Sites1 location across Saudi Arabia

Drugs / interventions tested

Conditions studied

Sponsor

Jouf University

Who can join

50 and older, male only, with Bone Density or Muscle Weakness. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims of this clinical trial is to evaluate the effect of an 8-week Whole Body Vibration (WBV) intervention on Bone Mineral Density (BMD), hand grip strength, and vitamin D levels in middle-aged men. Findings from this study will contribute to understanding whether WBV is a viable alternative to conventional exercise, especially for those with limitations in physical activity. Study Objectives: • Primary Objective: To assess the effectiveness of an 8-week WBV intervention in improving BMD, hand grip strength, and vitamin D levels compared to a placebo intervention.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Bone Density

Currently open trials in the same condition.

Other Jouf University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06644469.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing